John Libbey Eurotext

Annales de Biologie Clinique

Suivi biologique de l’héparinothérapie : intérêt clinique et aspects pratiques Volume 74, numéro 6, Novembre-Décembre 2016

  • [1] Gouin-Thibault I, Sié P, Siguret V. Héparine, dérives hépariniques et antagonistes de la vitamine K maniement, surveillance biologique, gestion des complications. 2012 ; Available from: site.geht.org/UserFiles/file/pratiques-professionnelles/GEHT_anticoagulants_Dec2012.pdf.
  • [2] Garcia D.A., Baglin T.P., Weitz J.I., Samama M.M. American College of Chest. Parenteral anticoagulants : antithrombotic therapy and prevention of thrombosis. 9th ed : American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141:e24S-43S.
  • [3] Hirsh J., Raschke R. Heparin and low-molecular-weight heparin : the Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126:188S-203S.
  • [4] Dawes J., Bara L., Billaud E., Samama M. Relationship between biological activity and concentration of a low-molecular-weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Haemostasis. 1986;16:116-122.
  • [5] Hacquard M., Perrin J., Lelievre N., Vigneron C., Lecompte T. Inter-individual variability of effect of 7 low molecular weight antithrombin-dependent anticoagulants studied in vitro with calibrated automated thrombography. Thromb Res. 2011;127:29-34.
  • [6] Al Dieri R., Alban S., Beguin S., Hemker H.C. Fixed dosage of low-molecular-weight heparins causes large individual variation in coagulability, only partly correlated to body weight. J Tromb Haemost. 2006;4:83-89.
  • [7] Kortchinsky T., Vigué B., Samama C.M. Antagonisation des héparines et des nouveaux anticoagulants. Ann Fr Anesth Reanim. 2013;32:37-49.
  • [8] Arixtra® (fondaparinux). Monographie du dictionnaire Vidal, 2012.
  • [9] De Caterina R., Husted S., Wallentin L., Andreotti F., Arnesen H., Bachmann F. Parenteral anticoagulants in heart disease : current status and perspectives (Section II). Position paper of the ESC Working Grloup on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost. 2013;109:769-786.
  • [10] Adcock DM. Sample integrity and preanalytical variables. Quality in laboratory hemostasis and thrombosis. Oxford : Wiley-Blackwell, 2009 :p. 31-42.
  • [11] De Caterina R., Husted S., Wallentin L., Andreotti F., Arnesen H., Bachmann F. Vitamin K antagonists in heart disease : current status and perspectives (Section III). Position paper of the ESC Working Glroup on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost. 2013;110:1087-1107.
  • [12] Boinot C DB, Droulle C, Hurtaud M.F, Polack B, Robert A (GEHT). Recommandations 2007 : prélèvements destinés aux tests d’Hémostase. http://site.geht.org/site/Pratiques-Professionnelles/Documents-GEHT/Variables-Preanalytiques/Recommandations-Variables-preanalytiques_69_722.htmL;2007.
  • [13] Delahousse B FC, Hurtaud-Roux M. Révision des conditions pré-analytiques en hémostase - GEHT 2015. 2015 ; Available from: http://site.geht.org/UserFiles/file/centrifugation/tableauau_synthese_recos_preA_GEHT2015.pdf.
  • [14] Favaloro E.J., Funk D.M., Lippi G. Pre-analytical variables in coagulation testing associated with diagnostic errors in hemostasis. Lab Med. 2012;43:1-10.
  • [15] Kitchen S., Gray E., Mackie I., Baglin T., Makris M., the Bc. Measurement of non-Coumarin anticoagulants and their effects on tests of Haemostasis : Guidance from the British Committee for Standards in Haematology. Br J Haematol. 2014;166:830-841.
  • [16] Adcock MD, Kottke-Marchant K, Marlar RA, Szamosi DI, Warunek DJ. Collection, transport, and processing of blood specimens for testing plasma-based coagulation assays and molecular hemostasis assays. Approved guideline: fifth edition (H21-A5). Clinical and Laboratory Standards Institute 2008 ; 28 : 1-33.
  • [17] Contant G., Gouault-Heilmann M., Martinoli J.L. Heparin inactivation during blood storage : its prevention by blood collection in citric acid, theophylline, adenosine, dipyridamole-C.T.A.D. mixture. Thromb Res. 1983;31:365-374.
  • [18] Ray M.J., Carroll P.A., Just S.J., Hawson G.A. A low volume specimen container suitableau for monitoring the aPTT of heparinized patients. Blood Coagul Fibrinolysis. 1993;4:805-807.
  • [19] Holbrook A., Schulman S., Witt D.M., Vandvik P.O., Fish J., Kovacs M.J. Evidence-based management of anticoagulant therapy : antithrombotic therapy and prevention of thrombosis. 9th ed. American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141:e152S-e184S.
  • [20] Kearon C., Ginsberg J.S., Julian J.A., Douketis J., Solymoss S., Ockelford P. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA. 2006;296:935-942.
  • [21] Heit J.A., Lahr B.D., Petterson T.M., Bailey K.R., Ashrani A.A., Melton L.J, 3rd. Heparin and warfarin anticoagulation intensity as predictors of recurrence after deep vein thrombosis or pulmonary embolism : a population-based cohort study. Blood. 2011;118:4992-4999.
  • [22] Menon V., Harrington R.A., Hochman J.S., Cannon C.P., Goodman S.D., Wilcox R.G. Thrombolysis and adjunctive therapy in acute myocardial infarction : the Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126:549s-s575.
  • [23] Amsterdam E.A., Wenger N.K., Brindis R.G., Casey D.E. Jr., Ganiats T.G., Holmes D.R. Jr. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes : executive summary:a report of the American college of cardiology/American heart association task force on practice guidelines. Circulation. 2014;130:2354-2394.
  • [24] Jobs A., Thiele H. ESC guidelines 2015. Non-ST-elevation acute coronary syndrome. Herz. 2015;40:1027-1033.
  • [25] (Afssaps) Afdssdpds. recommandations de bonne pratique prevention et traitement de la maladie thromboembolique veineuse en médecine 2009 ; Available from : http://ansm.sante.fr/var/ansm_site/storage/original/application/ae4209ebc36d7164d4b7c876ddeaabab.pdf.
  • [26] Zehnder J., Price E., Jin J. Controversies in heparin monitoring. Am J Hematol. 2012;87:S137-S140.
  • [27] Gouin-Thibaut I., Martin-Toutain I., Peynaud-Debayle E., Marion S., Napol P., Alhenc-Gelas M. Monitoring unfractionated heparin with APTT : a French collaborative study comparing sensitivity to heparin of 15 APTT reagents. Thromb Res. 2012;129:666-667.
  • [28] Bonar R.A., Favaloro E.J., Marsden K. External quality assurance for heparin monitoring. Semin Thromb Hemost. 2012;38:632-639.
  • [29] Cuker A., Raby A., Moffat K.A., Flynn G., Crowther M.A. Interlaboratory variation in heparin monitoring : lessons from the quality management program of Ontario coagulation surveys. Thromb Haemost. 2010;104:837-844.
  • [30] D’Angelo A., Seveso M.P., D’Angelo S.V., Gilardoni F., Dettori A.G., Bonini P. Effect of clot-detection methods and reagents on activated partial thromboplastin time (APTT). Implications in heparin monitoring by APTT. Am J Clin Pathol. 1990;94:297-306.
  • [31] Marlar R.A., Gausman J.N. The effect of instrumentation and laboratory site on the accuracy of the APTT-based heparin therapeutic range. Int J Lab Hematol. 2012;34:614-620.
  • [32] Bates S.M., Weitz J.I., Johnston M., Hirsh J., Ginsberg J.S. Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin. Arch Intern Med. 2001;161:385-391.
  • [33] Basu D., Gallus A., Hirsh J., Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med. 1972;287:324-327.
  • [34] Hirsh J., Bauer K.A., Donati M.B., Gould M., Samama M.M., Weitz J.I. Parenteral anticoagulants : American college of chest physicians evidence-based clinical practice guidelines (8th Edition). Chest. 2008;133:141S-S159.
  • [35] Cuker A. Unfractionated heparin for the treatment of venous thromboembolism : best practices and areas of uncertainty. Semin Thromb Hemost. 2012;38:593-599.
  • [36] Speer O., Schmugge M., Metzger C., Albisetti M. Reference ranges of coagulation tests. Methods Mol Biol. 2013;992:85-96.
  • [37] Olson J.D., Arkin C.F., Brandt J.T., Cunningham M.T., Giles A., Koepke J.A. College of American pathologists conference XXXI on laboratory monitoring of anticoagulant therapy : laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med. 1998;122:782-798.
  • [38] Cuker A., Ptashkin B., Konkle B.A., Pipe S.W., Whinna H.C., Zheng X.L. Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time. J Tromb Haemost. 2009;7:80-86.
  • [39] Despotis G.J., Avidan M.S., Hogue C.W. Jr. Mechanisms and attenuation of hemostatic activation during extracorporeal circulation. Ann Thorac Surg. 2001;72:S1821-S1831.
  • [40] Despotis G.J., Joist J.H., Goodnough L.T. Monitoring of hemostasis in cardiac surgical patients : impact of point-of-care testing on blood loss and transfusion outcomes. Clin Chem. 1997;43:1684-1696.
  • [41] Ferraris V.A., Ferraris S.P., Singh A., Fuhr W., Koppel D., McKenna D. The platelet thrombin receptor and postoperative bleeding. Ann Thorac Surg. 1998;65:352-358.
  • [42] George J.N., Pickett E.B., Saucerman S., McEver R.P., Kunicki T.J., Kieffer N. Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery. J Clin Invest. 1986;78:340-348.
  • [43] George J.N., Shattil S.J. The clinical importance of acquired abnormalities of platelet function. N Engl J Med. 1991;324:27-39.
  • [44] Khuri S.F., Wolfe J.A., Josa M., Axford T.C., Szymanski I., Assousa S. Hematologic changes during and after cardiopulmonary bypass and their relationship to the bleeding time and nonsurgical blood loss. J Thorac Cardiovasc Surg. 1992;104:94-107.
  • [45] Laffey J.G., Boylan J.F., Cheng D.C. The systemic inflammatory response to cardiac surgery : implications for the anesthesiologist. Anesthesiology. 2002;97:215-252.
  • [46] Levy J.H., Tanaka K.A. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 2003;75:S715-S720.
  • [47] Rinder C.S., Bohnert J., Rinder H.M., Mitchell J., Ault K., Hillman R. Platelet activation and aggregation during cardiopulmonary bypass. Anesthesiology. 1991;75:388-393.
  • [48] Rinder C.S., Mathew J.P., Rinder H.M., Bonan J., Ault K.A., Smith B.R. Modulation of platelet surface adhesion receptors during cardiopulmonary bypass. Anesthesiology. 1991;75:563-570.
  • [49] Sniecinski R.M., Chandler W.L. Activation of the hemostatic system during cardiopulmonary bypass. Anesth Analg. 2011;113:1319-1333.
  • [50] Warren O.J., Smith A.J., Alexiou C., Rogers P.L., Jawad N., Vincent C. The inflammatory response to cardiopulmonary bypass : part 1--mechanisms of pathogenesis. J Cardiothorac Vasc Anesth. 2009;23:223-231.
  • [51] Warren O.J., Watret A.L., de Wit K.L., Alexiou C., Vincent C., Darzi A.W. The inflammatory response to cardiopulmonary bypass : part 2--anti-inflammatory therapeutic strategies. J Cardiothorac Vasc Anesth. 2009;23:384-393.
  • [52] Blombaeck M., Blombaeck B., Wallen P. Determination of the level of heparin in the blood in the case of extracorporeal circulation during cardiac surgery. Rev Hematol. 1955;10:45-54.
  • [53] Young J.A., Kisker C.T., Doty D.B. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. Ann Thorac Surg. 1978;26:231-240.
  • [54] Lobato R.L., Despotis G.J., Levy J.H., Shore-Lesserson L.J., Carlson M.O., Bennett-Guerrero E. Anticoagulation management during cardiopulmonary bypass : a survey of 54 North American institutions. J Thorac Cardiovasc Surg. 2010;139:1665-1666.
  • [55] Taneja R., Fernandes P., Marwaha G., Cheng D., Bainbridge D. Perioperative coagulation management and blood conservation in cardiac surgery : a Canadian Survey. J Cardiothorac Vasc Anesth. 2008;22:662-669.
  • [56] Saad E.B., Costa I.P., Costa R.E., Inacio L.A. Jr., Slater C., Camiletti A. Safety of ablation for atrial fibrillation with therapeutic INR : comparison with transition to low-molecular-weight heparin. Arq Bras Cardiol. 2011;97:289-296.
  • [57] Cappato R., Calkins H., Chen S.A., Davies W., Iesaka Y., Kalman J. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3:32-38.
  • [58] Cappato R., Calkins H., Chen S.A., Davies W., Iesaka Y., Kalman J. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation. 2005;111:1100-1105.
  • [59] Calkins H., Kuck K.H., Cappato R., Brugada J., Camm A.J., Chen S.A. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation : recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace. 2012;14:528-606.
  • [60] Jobes D.R., Ellison N., Campbell F.W. Limit(ation)s for ACT. Anesth Analg. 1989;69:142-144.
  • [61] Jude B., Lasne D., Mouton C., de Moerloose P. Monitoring of heparin therapy during extracorporeal bypass : what are the remaining questions ? Ann Fr Anesth Reanim. 2004;23:589-596.
  • [62] Hussein H.M., Georgiadis A.L., Qureshi A.I. Point-of-care testing for anticoagulation monitoring in neuroendovascular procedures. Am J Neuroradiol. 2012;33:1211-1220.
  • [63] Davidson S.J., Tillyer M.L., Keogh J., Hall J., Kelleher A.A. Heparin concentrations in neonates during cardiopulmonary bypass. J Tromb Haemost. 2012;10:730-732.
  • [64] Lyon S.G., Lasser E.C., Stein R. Modification of an amidolytic heparin assay to express protein-bound heparin and to correct for the effect of antithrombin III concentration. Thromb Haemost. 1987;58:884-887.
  • [65] Gehrie E., Laposata M. Test of the month : the chromogenic antifactor Xa assay. Am J Hematol. 2012;87:194-196.
  • [66] Ignjatovic V., Newall F., Monagle P. Heparin concentrations in neonates during cardiopulmonary bypass : a rebuttal. J Tromb Haemost. 2012;10:1972.
  • [67] Potze W., Arshad F., Adelmeijer J., Blokzijl H., van den Berg A.P., Porte R.J. Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis. Br J Haematol. 2013;163:666-673.
  • [68] Lisman T., Porte R.J. Towards a rational use of low-molecular-weight heparin in patients with cirrhosis. Liver International. 2011;31:1063-1163.
  • [69] Long E., Pitfield A.F., Kissoon N. Anticoagulation therapy : indications, monitoring, and complications. Pediatr Emerg Care. 2011;27:55-61. quiz 62-4
  • [70] Koster A., Zittermann A., Schirmer U. Heparin resistance and excessive thrombocytosis. Anesth Analg. 2013;117:1262.
  • [71] Guermazi S., Znazen R. Les résistances aux traitements curatifs par l’héparine non fractionnée. Rev Med Interne. 2009;30:331-334.
  • [72] Jin J.P.E., Nguyen H., Krishnan G., Balise R., Bowen R.A. Prolonged aPTT relative to anti-Xa is associated with increased 30-day mortality in hospitalized patients treated with unfractionated heparin. ASH Annual Meeting Abstracts. 2011;118:1248.
  • [73] Alhenc-Gelas M., Jestin-Le Guernic C., Vitoux J.F., Kher A., Aiach M., Fiessinger J.N. Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Fragmin-Stufdy Group. Thromb Haemost. 1994;71:698-702.
  • [74] Leizorovicz A., Bara L., Samama M.M., Haugh M.C. Factor Xa inhibition : correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage. Haemostasis. 1993;23:89-98. Suppl. 1
  • [75] Boneu B., de Moerloose P. How and when to monitor a patient treated with low molecular weight heparin. Semin Thromb Hemost. 2001;27:519-522.
  • [76] Kovacs M.J., Keeney M., MacKinnon K., Boyle E. Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin. Clin Lab Haematol. 1999;21:55-60.
  • [77] Kitchen S., Iampietro R., Woolley A.M., Preston F.E. Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid : inter-assay variability. Thromb Haemost. 1999;82:1289-1293.
  • [78] Bates S.M., Greer I.A., Middeldorp S., Veenstra D.L., Prabulos A.M., Vandvik P.O. VTE, thrombophilia, antithrombotic therapy, and pregnancy : antithrombotic therapy and prevention of thrombosis, 9th ed:American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141:e691S-736S.
  • [79] Ni Ainle F., Wong A., Appleby N., Byrne B., Regan C., Hassan T. Efficacy and safety of once daily low molecular weight heparin (tinzaparin sodium) in high risk pregnancy. Blood Coagul Fibrinolysis. 2008;19:689-692.
  • [80] Smith M.P., Norris L.A., Steer P.J., Savidge G.F., Bonnar J. Tinzaparin sodium for thrombosis treatment and prevention during pregnancy. Am J Obstet Gynecol. 2004;190:495-501.
  • [81] Gibson P.S., Newell K., Sam D.X., Mansoor A., Jiang X., Tang S. Weight-adjusted dosing of tinzaparin in pregnancy. Thromb Res. 2013;131:e71-e75.
  • [82] Berresheim M., Wilkie J., Nerenberg K.A., Ibrahim Q., Bungard T.J. A case series of LMWH use in pregnancy : Should trough anti-Xa levels guide dosing ? Thromb Res. 2014;134:1234-1240.
  • [83] Goland S., Schwartzenberg S., Fan J., Kozak N., Khatri N., Elkayam U. Monitoring of anti-Xa in pregnant patients with mechanical prosthetic valves receiving low-molecular-weight heparin : peak or trough levels ? J Cardiovasc Pharmacol Ther. 2014;19:451-456.
  • [84] Barbour L.A., Oja J.L., Schultz L.K. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. Am J Obstet Gynecol. 2004;191:1024-1029.
  • [85] Chowdary P., Adamidou D., Riddell A., Aghighi S., Griffioen A., Priest P. Thrombin generation assay identifies individual variability in responses to low molecular weight heparin in pregnancy : implications for anticoagulant monitoring. Br J Haematol. 2015;168:719-727.
  • [86] Morange P.E., Alessi M.C. Thrombosis in central obesity and metabolic syndrome : mechanisms and epidemiology. Thromb Haemost. 2013;110:669-680.
  • [87] Frederiksen S.G., Hedenbro J.L., Norgren L. Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients. Br J Surg. 2003;90:547-548.
  • [88] Nutescu E.A., Spinler S.A., Wittkowsky A., Dager W.E. Low-molecular-weight heparins in renal impairment and obesity : available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother. 2009;43:1064-1083.
  • [89] Rowan B.O., Kuhl D.A., Lee M.D., Tichansky D.S., Madan A.K. Anti-Xa levels in bariatric surgery patients receiving prophylactic enoxaparin. Obes Surg. 2008;18:162-166.
  • [90] Wang T.F., Milligan P.E., Wong C.A., Deal E.N., Thoelke M.S., Gage B.F. Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients. Thromb Haemost. 2014;111:88-93.
  • [91] Rondina M.T., Wheeler M., Rodgers G.M., Draper L., Pendleton R.C. Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients. Thromb Res. 2010;125:220-223.
  • [92] Becker R.C., Spencer F.A., Gibson M., Rush J.E., Sanderink G., Murphy S.A. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J. 2002;143:753-759.
  • [93] Goudable C., Saivin S., Houin G., Sie P., Boneu B., Tonthat H. Pharmacokinetics of a low molecular weight heparin (Fraxiparine) in various stages of chronic renal failure. Nephron. 1991;59:543-545.
  • [94] Cestac P., Bagheri H., Lapeyre-Mestre M., Sie P., Fouladi A., Maupas E. Utilisation and safety of low molecular weight heparins : prospective observational study in medical inpatients. Drug Saf. 2003;26:197-207.
  • [95] Spinler S.A., Inverso S.M., Cohen M., Goodman S.G., Stringer K.A., Antman E.M. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment : analysis from the ESSENCE and TIMI 11B studies. Am Heart J. 2003;146:33-41.
  • [96] Siguret V., Pautas E., Fevrier M., Wipff C., Durand-Gasselin B., Laurent M. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg) : anti-Xa and anti-IIa activities over 10 days. Thromb Haemost. 2000;84:800-804.
  • [97] Mismetti P., Laporte-Simitsidis S., Navarro C., Sie P., d’Azemar P., Necciari J. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin). Thromb Haemost. 1998;79:1162-1165.
  • [98] Schmid P., Brodmann D., Odermatt Y., Fischer A.G., Wuillemin W.A. Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insufficiency. J Thromb Haemost. 2009;7:1629-1632.
  • [99] Siguret V., Gouin-Thibault I., Pautas E., Leizorovicz A. No accumulation of the peak anti-factor Xa activity of tinzaparin in elderly patients with moderate-to-severe renal impairment : the IRIS substudy. J Thromb Haemost. 2011;9:1966-1972.
  • [100] Bounameaux H., de Moerloose P. Is laboratory monitoring of low-molecular-weight heparin therapy necessary ? No. J Thromb Haemost. 2004;2:551-554.
  • [101] Harenberg J. Is laboratory monitoring of low-molecular-weight heparin therapy necessary ? Yes. J Thromb Haemost. 2004;2:547-550.
  • [102] Montalescot G., Collet J.P., Tanguy M.L., Ankri A., Payot L., Dumaine R. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation. 2004;110:392-398.
  • [103] Lim W., Dentali F., Eikelboom J.W., Crowther M.A. Meta-analysis : low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med. 2006;144:673-684.
  • [104] Newall F., Chan A.K., Ignjatovic V., Monagle P., Perinatal, paediatric haemostasis subcommittee of the S. Recommendations for developing uniform laboratory monitoring of heparinoid anticoagulants in children. J Thromb Haemost. 2012;10:145-147.
  • [105] Guyatt G.H., Akl E.A., Crowther M., Gutterman D.D., Schuunemann H.J., American college of chest physicians antithrombotic T. Executive summary : Antithrombotic therapy and prevention of thrombosis, 9th ed:American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141:7S-47S.
  • [106] Greene L.A., Law C., Jung M., Walton S., Ignjatovic V., Monagle P. Lack of anti-factor Xa assay standardization results in significant low molecular weight heparin (enoxaparin) dose variation in neonates and children. J Thromb Haemost. 2014;12:1554-1557.
  • [107] Levi M. Emergency reversal of antithrombotic treatment. Intern Emerg Med. 2009;4:137-145.
  • [108] Smogorzewska A., Brandt J.T., Chandler W.L., Cunningham M.T., Hayes T.E., Olson J.D. Effect of fondaparinux on coagulation assays : results of College of American pathologists proficiency testing. Arch Pathol Lab Med. 2006;130:1605-1611.
  • [109] Samama M.M., Martinoli J.L., LeFlem L., Guinet C., Plu-Bureau G., Depasse F. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor. Thromb Haemost. 2010;103:815-825.
  • [110] Linkins L.A., Dans A.L., Moores L.K., Bona R., Davidson B.L., Schulman S. Treatment and prevention of heparin-induced thrombocytopenia : Antithrombotic therapy and prevention of thrombosis, 9th ed:American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141:e495S-530S.
  • [111] Insert GGP. Arixtra (Fondaparinux Sodium) Injection. Research Triangle Park, NC : GlaxoSmithKline (GSK), 2004.
  • [112] Castellone D.D., Van Cott E.M. Laboratory monitoring of new anticoagulants. Am J Hematol. 2010;85:185-187.
  • [113] Nagler M., Haslauer M., Wuillemin W.A. Fondaparinux - data on efficacy and safety in special situations. Thromb Res. 2012;129:407-417.
  • [114] Pouplard C., Gueret P., Fouassier M., Ternisien C., Trossaert M., Regina S. Prospective evaluation of the ’4Ts’ score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost. 2007;5:1373-1379.
  • [115] Watson H., Davidson S., Keeling D. Guidelines on the diagnosis and management of heparin-induced thrombocytopenia : second edition. Br J Haematol. 2012;159:528-540.
  • [116] Dyke C.M., Smedira N.G., Koster A., Aronson S., McCarthy H.L., 2nd, Kirshner R. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass : the EVOLUTION-ON study. J Thorac Cardiovasc Surg. 2006;131:533-539.
  • [117] Smedira N.G., Dyke C.M., Koster A., Jurmann M., Bhatia D.S., Hu T. Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting : The results of the EVOLUTION-OFF study. J Thorac Cardiovasc Surg. 2006;131:686-692.
  • [118] Guy S., Kitchen S., Maclean R., Van Veen J.J. Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatroban. Int J Lab Hematol. 2015;37:834-843.